Royal London Hospital

London GT LON E1 1BB

14 studies enrolling now · 58 studies all time

What they study most

Acute Alcoholic Hepatitis, Acute Chest Pain, Acute Kidney Injury, Acute Liver Failure, Acute on Chronic Hepatic Failure, Alopecia Areata, Arthritis, Psoriatic, Atherosclerotic Cardiovascular Disease (ASCVD), Autosomal Dominant Hypocalcemia Type 1 (ADH1), Basal Cell Nevus Syndrome, Catecholamine-resistant Hypotension (CRH), Chronic Hepatitis C

Studies at this site

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — Recruiting now
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) — Recruiting now
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults — Recruiting now
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) — Recruiting now
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia — Recruiting now
Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome. — Recruiting now
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) — Recruiting now
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Recruiting now
Biology of Juvenile Myoclonic Epilepsy — Recruiting now
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) — Recruiting now
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) — Stopped early
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
A Long-term Extension Study of Ustekinumab in Pediatric Participants — Running, not enrolling
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Completed
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis — Stopped early
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes — Starting soon
The Merit WRAPSODY AV Access Efficacy Study (WAVE) — Completed
Atrasentan in Patients With IgA Nephropathy — Running, not enrolling
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Completed
Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) — Running, not enrolling
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) — Completed
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Running, not enrolling
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) — Completed
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome — Running, not enrolling
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation — Completed
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF — Completed
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) — Completed
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) — Stopped early
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period — Completed
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome — Completed
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) — Completed
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia — Running, not enrolling
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis — Completed
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
Tenecteplase in Wake-up Ischaemic Stroke Trial — Status unconfirmed
Lubiprostone in Children With Functional Constipation — Completed
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI — Completed
Lubiprostone for Children With Constipation — Completed
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD — Stopped early
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed